Chapter 20: Antianginal Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine you're shoveling snow.

The absolute worst.

Right.

It's freezing outside.

Your heart is just pounding.

Yeah.

And well, it's demanding more oxygen with every single beat just to keep up with the exertion.

But inside one of your coronary arteries, there's this tiny atherosclerotic plaque forming a bottleneck.

A literal roadblock.

Exactly.

The blood and the crucial oxygen it carries, it just can't get through fast enough.

Your heart muscle essentially begins to starve.

Today, we are looking at the exact chemical keys that pharmacology uses to, well, stop that starvation in its tracks.

Because that starvation, that is the fundamental biological problem of heart disease or coronary artery disease.

It's essentially a biological budget deficit.

I love that analogy.

A budget deficit.

Right.

Because the myocardium is spending way more oxygen than the coronary arteries can deposit.

And our mission today is to decode the clinical puzzle of anti -engine drugs.

Yes.

And if you are a college pharmacology student seeing this topic for the very first time, we're going to translate all that dense drug information into plain, unforgettable logic.

We're doing a deep dive into Chapter 20 of Lippincott Illustrated Reviews.

Pharmacology, the seventh edition.

And we're sticking strictly to the text, moving right through the foundational physiology up to clinical use, adverse effects, all of it.

Exactly.

In the sequence you'd find in a standard curriculum.

No outside fluff.

But, you know, before we even touch a prescription pad, the clinical guidelines always start with the foundation, which is lifestyle modifications.

Right.

The basics.

Smoking cessation, weight management.

Yeah.

Physical activity and controlling those major risk factors like hypertension, diabetes, and dyslipidemia.

You have to fix that foundation first to actually reduce overall mortality.

But when lifestyle just isn't enough, that's when we turn to the pharmacology.

Which means we need to understand the three distinct faces of angina because, well, before you can treat the chest pain, you have to know exactly what kind of deficit you're dealing with.

So let's start with the most common one, right?

Stable or effort -induced classic angina.

Yeah.

Classic angina.

This is caused by a fixed obstruction in a coronary artery, like that atherosclerotic plaque you mentioned earlier with the snow shoveling.

Roadblock.

Exactly.

Because the obstruction is a physical fixed barrier, the blood supply is essentially capped.

It has maximum limit.

So when myocardial oxygen demand goes up during exercise or even emotional stress, the supply simply cannot meet the demand.

And that results in ischemia.

The atypical presentation is a sudden, severe, really crushing chest pain.

Right.

The kind that can radiate to the neck, jaw, back, arms.

But here's where it gets really interesting clinically.

Atypical presentations are incredibly common.

Oh, absolutely.

Like instead of that crushing chest pain, a patient might just experience extreme fatigue or nausea, sweating.

And the text points out these atypical presentations are significantly more common in women, diabetic patients, and the elderly.

Which is why understanding the physical mechanism is so, so critical.

There's a classic visual model in the chapter, figure 20 .2, to illustrate this.

Picture a pipe representing your coronary artery.

Okay, gaba pipe.

If plaque obstructs 50 % of that pipe, you have the potential for angina, but blood is generally still flowing fine at rest.

Right.

But if that obstruction grows to 70%, the margin for error is totally gone.

The moment you start shoveling snow, you get exercise -induced angina.

But here is the really elegant part of the pharmacology.

If we use a vasodilator drug to decrease the vascular tone, relaxing the smooth muscle in that vessel wall,

the pipe widens.

The physical plaque hasn't changed at all.

Exactly.

But because the vessel is wider around it, that 70 % obstruction suddenly behaves like a 30 % obstruction.

Blood flows freely again, and the pain just disappears.

And true to its name, stable angina is predictable.

It's triggered by a consistent amount of effort, and it's promptly relieved by rest or nitroglycerin.

Okay, but what happens when the pain changes?

That brings us to our second type, which is unstable angina.

And this is a medical emergency.

Yeah, a true emergency.

It falls under the umbrella of acute coronary syndrome, or ACS.

This is chest pain that's rapidly increasing in frequency or duration and intensity.

Exactly.

It happens with progressively less effort.

If a patient has resting chest pain that lasts longer than 20 minutes, or if it's a brand new onset of really severe angina, you have to suspect it's unstable.

And crucially, it is not relieved by rest or nitroglycerin.

Right.

But wait, let's pause here.

Because if an unstable angina attack is an emergency caused by a plaque rupturing and a blood clot forming a thrombus, isn't that just a heart attack?

How is this clinically different from a full -blown myocardial infarction in a MMI?

That is the absolute critical diagnostic distinction you have to make.

In acute coronary syndrome, that thrombus forms.

If the occlusion isn't cleared, the cardiac muscle tissue is completely deprived of oxygen, and it eventually dies.

The tissue necrosis.

Right.

That cellular death is necrosis, and that is a myocardial infarction.

And when those cells die, they essentially like burst open and spill their internal contents right into the bloodstream.

Precisely.

So an MI is confirmed by increases in specific serum biomarkers, specifically troponins and creatine kinase.

Oh, okay.

But in unstable angina, the ischemia is incredibly severe, but the tissue hasn't undergone necrosis yet.

Because the cells haven't died, those biomarkers of myocardial necrosis are absent.

Exactly.

Biomarkers mean tissue death, which means MI.

No biomarkers means unstable angina.

That makes total sense.

Okay, so that leaves our third type of angina, which frankly feels a bit like a wild card.

Prince metal, also known as variant or vasospastic angina.

It's definitely an anomaly.

This is an uncommon pattern that actually occurs at rest.

It's not caused by the heart working harder at all.

So no snow shoveling required.

None.

It's caused by a sudden decrease in blood flow because the smooth muscle of the coronary artery literally spasms shut.

So it's completely unrelated to physical activity or heart rate.

You could just be sitting on the couch doing absolutely nothing, and suddenly the pipe just clamps itself shut.

Exactly.

The patient might have underlying atherosclerosis too, but the acute attack itself is driven by the spasm.

And because of that specific mechanism, it responds promptly to coronary vasodilators.

Like nitroglycerin and calcium channel blockers?

Right.

Things that chemically force that smooth muscle to relax.

Okay, so we have a heart starving for oxygen due to either a fixed plaque, a growing clot, or a sudden spasm.

How do we logically deploy our pharmacology toolkit to fix this?

Well, the overarching clinical strategy is all about balancing that oxygen supply and demand equation.

We do that by altering four main hemodynamic parameters.

Blood pressure, venous return, heart rate, and contractility.

The tech maps this out brilliantly in figure 20 .4 of the treatment algorithm.

Basically, if a patient with stable ischemic heart disease experiences an acute angina attack, they need immediate relief.

That for daily maintenance, to prevent those attacks from happening in the first place, your first line of defense is a beta blocker.

Always the first line.

And if you maximize that beta blocker and the patient still doesn't have adequate relief, you don't just stop.

You add a calcium channel blocker or a long acting nitrate.

And if they are still having symptoms after that, you add a sodium channel blocker called ranilazine.

But we can't look at angina in a vacuum, right?

There's this fascinating concomitant disease matrix in figure 20 .3 we have to consider because the patient's other health conditions entirely dictate our drug choices.

Oh, absolutely.

For instance, if a patient has asthma or COPD, beta blockers are generally dangerous because they can trigger bronchus spasms in the lungs.

Which you really don't want.

Right.

So we rely on calcium channel blockers and long acting nitrates instead.

Conversely, if a patient just had a recent myocardial infarction, beta blockers are heavily favored.

So let's dive deep into that first line therapy.

The beta -edrenergic blockers, they are the go -to maintenance drug.

But how are they physically changing the heart's oxygen budget?

It comes down to blocking beta -1 receptors in the heart.

By blocking these receptors from binding with adrenaline and noradrenaline, beta blockers decrease the heart rate and they decrease contractility.

Which is the physical force of the heart squeeze.

Exactly.

And they decrease overall cardiac output and blood pressure.

All of this massively drops the myocardium's oxygen demand, both during exertion and at rest.

So if the heart isn't working as hard, it doesn't need as much oxygen.

Meaning you don't get the ischemia and the pain.

The guidelines recommend them as the initial anti -anginal therapy for almost all patients.

They're incredibly effective.

They're proven to reduce the risk of death and MI in patients with a prior MI.

And they improve heart failure with reduced ejection fraction.

But I know drug choice within the class really matters.

It absolutely does.

So propranolol is the prototype beta blocker, but it is non -selective.

Meaning it blocks beta -1 receptors in the heart and beta -2 receptors in the lungs.

Right.

So cardioselective agents, specifically metoprolol and atenolol, are preferred for angina.

Though it's vital to note that at high doses, all beta blockers lose their selectivity and start hitting those beta -2 receptors anyway.

And there are also some strict contraindications.

You must avoid beta blockers entirely in patients with severe bradycardia.

Right.

Because you never want to slow down a heart that's already beating dangerously slow.

Definitely not.

And the literature specifically warns to avoid agents with intrinsic

sympathomimetic activity,

or ISA.

Drugs like pindolol.

What actually is ISA?

It sounds like a contradiction if the drug is supposed to be a blocker.

It is a bit of a paradox, honestly.

A drug with ISA is a partial agonist.

So while it blocks full strength adrenaline from binding to the receptor, the drug itself still weakly stimulates that same receptor.

Weird.

Yeah.

It's like putting a wedge under a door.

It stops the door from opening wide, but it guarantees the door stays slightly open.

For an angina patient, we want the heart completely rested so that weak stimulation from an ISA drug is just counterproductive.

That makes perfect sense.

Now let me push back on that recommended for all patients rule you

The beta blockers are so amazing at dropping oxygen demand.

Why are they explicitly contraindicated for Prince metal variant angina?

Ah, it's all about the underlying cause we discussed.

Vasospastic angina is a pipe squeezing problem, not a heart rate problem.

Right, the spasm.

Exactly.

Beta blockers lower heart rate and contractility, but they do nothing to relax the coronary arteries.

In fact, by blocking beta receptors, they can leave alpha receptors completely unopposed.

Which means?

Which can actually trigger more intense vasoconstriction and significantly worsen the vasospasm symptoms.

Wow.

Okay.

So it actually makes it worse.

One last critical warning on beta blockers.

Wait, if we block these beta receptors continuously for months,

doesn't the body recognize that and respond by building more receptors to compensate?

It does.

Like turning up the gain on a microphone because the signal is too low.

Yeah.

So if you just quit the drug, cold turkey, suddenly you have a heart flooded with extra receptors, making it wildly hypersensitive to adrenaline.

You've just perfectly described receptor upregulation.

That is exactly why you can never abruptly discontinue a beta blocker.

Never stop cold turkey.

Never.

If you stop abruptly, you risk rebound angina, severe hypertension, or even a myocardial infarction.

The dose must be gradually tapered off over two to three weeks.

Okay.

So beta blockers are great at slowing the heart down, but what if the problem isn't the heart rate?

What if the literal pipes are spasming shut or we need to drop the vascular resistance?

Slowing the heart won't fix a clamped pipe.

No, it won't.

To force those vessels open, we have to change the cell's chemistry using our second class, calcium channel blockers or CCBs.

Right.

And to understand why CCBs work, we really have to look at the microscopic chaos of ischemia.

When cardiac or smooth muscle tissue becomes hypoxic -starved of oxygen, it causes the cell membrane to depolarize.

And that depolarization opens voltage -gated channels and boom, calcium floods into the cells.

Exactly.

And calcium is the fundamental trigger for muscular contraction.

So this sudden flood of calcium forces a bunch of ATP -consuming enzymes into overdrive.

So the cell is literally burning through its final energy stores while it's already starving for oxygen.

Right, which just creates a vicious cycle that massively worsens the ischemia.

Calcium channel blockers protect the tissue by blocking that calcium influx in both the coronary and systemic arterial beds.

Because if calcium can't get in, the smooth muscle physically cannot contract as hard.

Exactly.

All CCBs act as arterial or vasodilators.

They decrease smooth muscle tone and vascular resistance.

And by decreasing that resistance, which is the afterload, the heart doesn't have to push as hard against the blood vessels.

Reducing myocardial oxygen consumption.

Yep.

And because they relax coronary arteries directly, they are highly objective for vasospastic angina.

Now, we have two distinct families of CCBs, the dihydropyridines and the non -dihydropyridines.

I like to think of them as the plumbers and the electricians.

I like that.

But why do they act differently if they're both just blocking calcium?

It all comes down to receptor affinity.

The plumbers, the dihydropyridines like amyloidapine and nephetapine, they have a remarkably high affinity for the specific type of calcium channels found in vascular smooth muscle.

So they target the pipes, not the heart's electrical grid.

Right.

Amyloidapine functions mainly as an arteriolar vasodilator with very minimal effect on cardiac conduction.

But there is a huge red flag warning for the dihydropyridines.

Short -acting versions must be avoided in coronary artery disease.

Yes.

That is crucial.

Because if you plunge the blood too fast with the short -acting vasodilator, the brain panics and triggers a reflex tachycardia, right?

Yeah.

It tells the heart to beat faster to compensate.

Exactly.

That increased heart rate burns way more oxygen and that there is evidence it actually increases mortality after an MI.

You always, always want extended release formulations.

Okay.

So if they are the plumbers, tell us about the electricians, the non -dihydropyridines.

These are verapamil and diltiasm.

Their receptor affinity draws them to the calcium channels in the heart's pacemaker cells.

They directly affect the electrical system, slowing atrioventricular or AV conduction.

Which decreases the heart rate.

Right.

And verapamil has a much stronger negative inotropic effect than amyloidapine, meaning it significantly weakens the physical force of the heart's contraction, but it is a weaker vasodilator.

And what about diltiasm?

Diltiasm sits right in the middle.

It slows AV conduction, but is also a solid coronary artery vasodilator.

But because the electricians weaken the force of the heart's contraction, there's a major contraindication we have to mention.

They can significantly worsen heart failure.

Yes.

Their negative inotropic effect is dangerous for a heart that is already failing to pump efficiently, so they must be avoided in those patients.

And verapamil is also contraindicated if a patient has pre -existing AV conduction Yeah, correct.

Which brings us to the third major class.

Organic nitrates.

These are effective across the board in stable, unstable, and variant angina.

But to appreciate them, we have to trace the biochemical breadcrumbs.

Okay, let's follow the pathway in figure 20 .5.

When a patient takes a nitrate, it enters the smooth muscle cell and converts into nitrite ions.

Right.

Those nitrite ions then convert into nitric oxide.

And nitric oxide is the magic key.

It activates an intracellular enzyme called guanylate cyclis.

And guanylate cyclis then ramps up the synthesis of a messenger molecule called CGMP.

And that elevated CGMP is what ultimately leads to the dephosphorylation of the myosin light chain.

Which, in plain English,

it biochemically forces the vascular smooth muscle to relax.

So what's the therapeutic effect of that relaxation?

Nitrates, like nitroglycerin, predominantly cause dilation of the large veins.

Right, the veins.

By opening up the veins, you reduce venous return to the heart, a concept called preload.

Less blood rushing into the heart means less blood the heart has to forcefully pump out.

Exactly, which dramatically reduces its workload and oxygen demand.

But the pharmacokinetics, how the body processes the drug,

really dictates how we use them.

Sublingual nitroglycerin kicks in within one to three minutes, making it the absolute drug of choice for prompt relief of an ongoing angina attack.

And the reason it's given as a tablet or spray under the tongue is because of the first pass effect.

Figure 20 .6 shows this nicely.

If you swallowed it, the liver would metabolize and destroy almost all of it before it ever reached your systemal circulation.

So sublingual and transdermal patches bypass the liver entirely.

Exactly.

But if you need long -lasting daily prevention, you use an oral drug like isosorbide mononatrate.

It takes 30 minutes to kick in, but because it is chemically stable against hepatic breakdown, its effects last for 12 to 24 hours.

Because they are powerful vasodilators, the most common adverse effect is just a headache, right?

Yeah.

Throbbing headaches are very common.

High doses can also cause postural hypertension, flushing, and that reflex tachycardia we mentioned earlier.

But there is one drug interaction that is absolutely critical to remember.

Oh, the PDE5 inhibitors.

Yes.

Phosphodiesterase type 5 inhibitors, like sildenafil.

Wait, let's look at the mechanism there.

PDE5's entire biological job is to break down CGMP.

So if a patient takes a nitrate, which acts like a factory mass -producing CGMP, and then takes a PDE5 inhibitor, which destroys the body's ability to clean up that CGMP.

You get a catastrophic flood of CGMP.

The smooth muscle relaxes to an extreme degree, intensely potentiating the nitrate.

Which means?

It triggers a massive, sudden, and potentially lethal drop in blood pressure.

They are strictly contraindicated together.

Good to know.

And there's another major clinical quirk with nitrates,

colorants.

If transdermal patches are so convenient, why can't a patient just slap one on and wear it 24 -7?

Because the blood vessels become desensitized to the vasodilation incredibly rapidly.

If you wear a patch constantly, it simply stops working.

Really?

Yeah.

To overcome this tolerance, patients require a daily nitrate -free interval of 10 -12 hours just to restore the vessel's sensitivity.

Usually you take the patch off at night, right?

Since you're sleeping and myocardial oxygen demand is at its absolute lowest anyway.

Normally, yes.

But there's a fascinating exception for patients with variant angina.

The vasospasm, folks.

Right.

Their vasospasm attacks often happen early in the morning, largely due to circadian surges and catecholamines.

So for variant angina, that 10 -12 hour nitrate -free interval should actually be scheduled for the late afternoon.

Ah, ensuring the patch is actively protecting them during the morning danger zone.

Exactly.

So what if a patient has run through this entire algorithm?

They are on beta blockers, CCBs, and nitrates, but they are still having chest pain.

That brings us to our backup parachute,

the sodium channel blocker, ranolazine.

Our last resort.

How does the backup parachute actually work?

Ranolazine works by inhibiting the late phase of the sodium current inside the heart cells.

By slowing down that late sodium influx, it reduces the overload of intracellular sodium.

Okay, less sodium.

And because the sodium and calcium exchange mechanisms in the cell are physically linked, less sodium inside means the cell stops pulling in extra calcium.

Ah, so it indirectly stops the calcium overload.

Precisely.

And less calcium overload improves the heart's diastolic function.

The heart relaxes and fills more easily, which balances the oxygen supply and demand equation without actually altering hemodynamic parameters.

Like heart rate or blood pressure.

Right, it doesn't touch them.

But ranolazine comes with some distinct quirks.

The literature points out a pretty bizarre medical mystery.

Its anti -anginal effects are considerably less effective in women than in men, and science currently has no definitive explanation for why.

It's a striking detail for sure.

And pharmacokinetically, it requires intense monitoring.

It is extensively metabolized in the liver by the CYP3A family and CYP2D6 enzymes.

It is also a substrate for p -glycoprotein.

P -glycoprotein essentially acts like a cellular bouncer.

Right.

Its job is to pump foreign substances, including drugs, back out of the cell.

That's a great way to put it.

So if a patient takes another drug that inhibits that bouncer, or inhibits those CYP liver enzymes, the ranolazine isn't cleared out.

It builds up to toxic levels in the body, leading to a massive list of drug interactions.

Exactly.

And the most dangerous consequence of that buildup is that ranolazine can prolong the QT interval on an EKG.

It must be strictly avoided with any other drugs that cause QT prolongation to prevent triggering deadly cardiac arrhythmias.

So let's tie this entire clinical puzzle together.

Let's look at the study questions at the end of the chapter.

Imagine you have a patient with uncontrolled angina.

He is maxed out on his data blocker, his heart rate is low, his blood pressure is low, and he absolutely cannot tolerate increasing his isosaur by mononatrate because the vasodilation gives him debilitating headaches.

What is the next move?

You have to map out the mechanisms.

You can't use verapamil, diltiasm, or nyctopine because his blood pressure and heart rate are already low.

Right.

Those CCBs would drop them to dangerous levels.

Exactly.

And he's maxed on beta blockers.

Nitrates cause severe side effects.

So the only logical safe move left on the board is ranolazine.

Because it improves diastolic function without touching the heart rate or blood pressure, it's the perfect targeted add -on.

It perfectly illustrates the elegance of cardiovascular pharmacology.

You really have to consider the whole patient, their vitals, their concomitant diseases, and the specific microscopic mechanisms of the drugs.

You do.

It also raises a fascinating question to think about.

We've spent all this time talking about manually blocking channels and altering enzymes with daily pills, just constantly managing this delicate biological budget deficit.

But as genetic targeting gets more precise, will we eventually see a day where we don't need these daily interventions at all?

What if we could simply recode the smooth muscle sensitivity to calcium permanently, solving the supply and demand equation at the genetic level?

Man, that's an incredible thought.

Something for you to mull over after this deep dive.

Until then, the clinical algorithm we mapped out today remains our best tool.

To you, the student listening right now, thank you for trusting us to decode this puzzle with you.

We know pharmacology can feel overwhelming, but when you focus on the why behind the mechanisms, the pieces really do just fall into place.

From the last minute lecture team, happy studying, and we'll catch you on the next deep dive.